Compare Crispr Therapeutics AG (CRSP) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ralph Lauren Corp — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while Ralph Lauren Corp trades at $367.77 (market cap $21.52B). The key difference: Ralph Lauren Corp is far larger — about 4.3× Crispr Therapeutics AG's market cap, and Ralph Lauren Corp pays a 1.11% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Ralph Lauren Corp for 84 Days on average.
| CRSP | RL | |
|---|---|---|
Market Cap | $5.06B | $21.52B |
Volume | 1,678,371 | 454,217 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $414.25 |
52-Week Low | $44.34 | $309.29 |
Typical Hold Time | 77 Days | 84 Days |
Enterprise Value | $3.48B | $22.58B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Ralph Lauren (RL) trades at $367.39, down 0.35% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 70.27% gross margins and 37.54% ROE, while consistently beating earnings estimates. Recent news highlights global expansion through new store openings and AI-driven customer experience enhancements. Cash flow remains positive at $258.80M for 2025, supporting the $1.00 dividend declared for October 2026 payment.
The stock presents a compelling value opportunity with analyst consensus target of $456.67 representing 24% upside. Strong brand positioning and operational efficiency drive growth, though competitive pressures and market volatility pose risks. Institutional sentiment remains bullish with 67% buy ratings, suggesting confidence in the company's luxury market strategy and financial performance trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
